BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 16841142)

  • 1. Microvessel density and p53 in detecting cervical cancer by FDG PET in cases of suspected recurrence.
    van der Veldt AA; Hooft L; van Diest PJ; Berkhof J; Buist MR; Comans EF; Hoekstra OS; Molthoff CF
    Eur J Nucl Med Mol Imaging; 2006 Dec; 33(12):1408-16. PubMed ID: 16841142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clarifying the diagnosis of clinically suspected recurrence of cervical cancer: impact of 18F-FDG PET.
    van der Veldt AA; Buist MR; van Baal MW; Comans EF; Hoekstra OS; Molthoff CF
    J Nucl Med; 2008 Dec; 49(12):1936-43. PubMed ID: 18997039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical impact of 2-deoxy-2-[18F]fluoro-D-glucose (FDG)-positron emission tomography (PET) on treatment choice in recurrent cancer of the cervix uteri.
    Bjurberg M; Brun E
    Int J Gynecol Cancer; 2013 Nov; 23(9):1642-6. PubMed ID: 24177254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical impact of FDG-PET imaging in post-therapy surveillance of uterine cervical cancer: from diagnosis to prognosis.
    Chung HH; Kim SK; Kim TH; Lee S; Kang KW; Kim JY; Park SY
    Gynecol Oncol; 2006 Oct; 103(1):165-70. PubMed ID: 16574205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of PET scanning in the detection of recurrent cervical cancer.
    Havrilesky LJ; Wong TZ; Secord AA; Berchuck A; Clarke-Pearson DL; Jones EL
    Gynecol Oncol; 2003 Jul; 90(1):186-90. PubMed ID: 12821362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positron emission tomography with 2-deoxy-2-[(18)F]fluoro-D-glucose for evaluating local and distant disease in patients with cervical cancer.
    Wong TZ; Jones EL; Coleman RE
    Mol Imaging Biol; 2004; 6(1):55-62. PubMed ID: 15018829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDG-PET in the detection of recurrence of uterine cervical carcinoma following radiation therapy--tumor volume and FDG uptake value.
    Sakurai H; Suzuki Y; Nonaka T; Ishikawa H; Shioya M; Kiyohara H; Katoh H; Nakayama Y; Hasegawa M; Nakano T
    Gynecol Oncol; 2006 Mar; 100(3):601-7. PubMed ID: 16257440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between the immunohistochemistry of the primary tumour and 18F-FDG-PET/CT at recurrence in patients with well-differentiated thyroid carcinoma.
    Lansoy-Kuhn C; Picquenot JM; Edet-Sanson A; Mechken F; Laberge-Le Couteulx S; Cornic M; Vera P
    Nucl Med Commun; 2013 Apr; 34(4):340-6. PubMed ID: 23407367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of local relapse and distant metastasis in patients with definitive chemoradiotherapy-treated cervical cancer by deep learning from [
    Shen WC; Chen SW; Wu KC; Hsieh TC; Liang JA; Hung YC; Yeh LS; Chang WC; Lin WC; Yen KY; Kao CH
    Eur Radiol; 2019 Dec; 29(12):6741-6749. PubMed ID: 31134366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologic correlation of 2-[18F]-fluoro-2-deoxy-D-glucose uptake on positron emission tomography in thymic epithelial tumors.
    Kaira K; Endo M; Abe M; Nakagawa K; Ohde Y; Okumura T; Takahashi T; Murakami H; Tsuya A; Nakamura Y; Naito T; Hayashi I; Serizawa M; Koh Y; Hanaoka H; Tominaga H; Oriuchi N; Kondo H; Nakajima T; Yamamoto N
    J Clin Oncol; 2010 Aug; 28(23):3746-53. PubMed ID: 20625125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does diabetes mellitus influence the efficacy of FDG-PET in the diagnosis of cervical cancer?
    Chang YC; Yen TC; Ng KK; See LC; Lai CH; Chang TC; Tsai CS; Hong JH; Hsueh S; Chou HH
    Eur J Nucl Med Mol Imaging; 2005 Jun; 32(6):647-52. PubMed ID: 15703931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (18F-FDG-PET) in the diagnosis of recurrence and lymph node metastasis of cervical cancer.
    Umesaki N; Tanaka T; Miyama M; Kawabe J; Okamura T; Koyama K; Ochi H; Ogita S
    Oncol Rep; 2000; 7(6):1261-4. PubMed ID: 11032926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. F18-FDG-PET/CT in the evaluation of patients with suspected recurrent or persistent locally advanced cervical carcinoma.
    Cetina L; Serrano A; Cantú-de-León D; Pérez-Montiel D; Estrada E; Coronel J; Hernández-Lucio M; Dueñas-González A
    Rev Invest Clin; 2011; 63(3):227-35. PubMed ID: 21888286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18F-fluorodeoxyglucose positron emission tomography in patients with recurrent ovarian cancer: in comparison with vascularity, Ki-67, p53, and histologic grade.
    Cho SM; Park YG; Lee JM; Byun JY; Lee JM; Lee KY; Park GS; Kim HS; Lee BY; Lee KH; Song KS
    Eur Radiol; 2007 Feb; 17(2):409-17. PubMed ID: 16786320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative benefits and limitations of 18F-FDG PET and CT-MRI in documented or suspected recurrent cervical cancer.
    Yen TC; Lai CH; Ma SY; Huang KG; Huang HJ; Hong JH; Hsueh S; Lin WJ; Ng KK; Chang TC
    Eur J Nucl Med Mol Imaging; 2006 Dec; 33(12):1399-407. PubMed ID: 16847653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of early recurrence with 18F-FDG PET in patients with cervical cancer.
    Ryu SY; Kim MH; Choi SC; Choi CW; Lee KH
    J Nucl Med; 2003 Mar; 44(3):347-52. PubMed ID: 12620999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biologic correlates of ¹⁸F-FDG uptake on PET in pulmonary pleomorphic carcinoma.
    Kaira K; Endo M; Abe M; Nakagawa K; Ohde Y; Okumura T; Takahashi T; Murakami H; Tsuya A; Nakamura Y; Naito T; Hayashi I; Kondo H; Nakajima T; Yamamoto N
    Lung Cancer; 2011 Feb; 71(2):144-50. PubMed ID: 20646779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolo-volumetric parameters of 18F-FDG-PET can predict expression of EGFR and HIF 1alpha in uterine cervical cancer.
    Surov A; Meyer HJ; Höhn AK; Schob S; Winter K; Sabri O; Purz S
    Cancer Biomark; 2019; 24(1):135-140. PubMed ID: 30530968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of FDG PET in patients with cervical cancer.
    Sugawara Y; Eisbruch A; Kosuda S; Recker BE; Kison PV; Wahl RL
    J Nucl Med; 1999 Jul; 40(7):1125-31. PubMed ID: 10405131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.